Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

A Trial of ALIMTA (Pemetrexed) Plus Irinotecan in Patients Who Have Been Previously Treated For Metastatic Colorectal Cancer.

ABSTRACT: This is a non-randomized study in patients who have received prior 5-FU therapy for colorectal cancer. The objective of this trial is to establish a maximum tolerated dose of ALIMTA and irinotecan given in combination as well as to assess the safety and efficacy of this combination for patients with locally advanced or metastatic colorectal cancer. ALIMTA and irinotecan will be given every 21 days.

DISEASE(S): Colorectal Cancer,Colorectal Neoplasms

PROVIDER: 2007428 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Json Xml

Similar Datasets

Phase II study of therapy selected by tumor molecular profiling in patients with previously treated metastatic pancreatic cancer. A study of the Stand Up to Cancer (SU2C) study consortium

Project description:The study accrued 49 subjects, and 48 underwent a tumor biopsy. and MP based therapy was administered to 35 patients. Study therapy was not given in 13 subjects either due to insufficient tumor on biopsy (n=8) or due to worsening cancer related symptoms after biopsy (n=5) . The demographics of evaluable patients (n=35) are M/F (59%/41%), with and age range was 34-78 (median 63 years). Time from first diagnosis of mPC to biopsy ranged from 5.8-26.7 months (median 16.1 months). Patients had 1-6 prior regimens with a median of 2. The most common IHC targets were topoisomerase 1 or 2, thymidylate synthase, ERCC1 and SPARC. Only commercially available agents were prescribed. Common regimens/agents recommended were FOLFIRI, FOLFOX, irinotecan and doxorubicin. Response rate was 9% , overall median survival of 6 months and 1 year survival was 21%.

2014-12-31 | GSE64462 | GEO

Pemetrexed for previously treated patients with metastatic gastric cancer: a prospective phase II study.

Project description: Not available

| S-EPMC4453460 | biostudies-literature

Expression data of squamous cervical carcinoma after chemotherapy

Project description:The patients with locally advanced squamous cervical cancer (SCC) were examined in this study. All patients received neoadjuvant chemotherapy followed by radical hysterectomy. Tumor response against NAC was determined based on RECIST criterior. Gene-expression profiles of SCC were determined using Human Genome GeneChip arrays U133. SCC patients who had undergone radical hysterectomy after NAC were studied. To identify molecular signatures to predict response to NAC using Irinotecan/Nedaplatin, gene expression profiles were compared between NAC Reponder and Non-responder.

2015-06-23 | E-GEOD-70035 | biostudies-arrayexpress

A phase II study of guadecitabien combined with irinotecan vs regorafenib or TAS-102 in previously treated metastatic colorectal cancer patients

Project description:A phase II study of guadecitabien combined with irinotecan vs regorafenib or TAS-102 in previously treated metastatic colorectal cancer patients

2023-03-31 | GSE226221 | GEO

Lorlatinib Versus Pemetrexed-Based Chemotherapy in Patients With ALK-rearranged NSCLC Previously Treated With Alectinib.

Project description: Not available

| S-EPMC9046446 | biostudies-literature

Pemetrexed plus cisplatin in patients with previously treated advanced sarcoma: a multicenter, single-arm, phase II trial.

Project description: Not available

| S-EPMC8424216 | biostudies-literature

A phase I/II study of pemetrexed with sirolimus in advanced, previously treated non-small cell lung cancer.

Project description: Not available

| S-EPMC6626857 | biostudies-literature

Longitudinal biopsies of fusion-positive rhabdomyosarcoma orthotopic xenografts

Project description:In this experiment, 3 mice were implanted orthotopically with a patient-derived xenograft, SJRHB013759_X14. After tumor engraftment and visible nodule formation, all 3 mice underwent therapy. One mouse received vehicle control (saline), while two mice were treated with a combination of vincristine and irinotecan, to mimic salvage therapy for relapsed rhabdomyosarcoma. Sedated needle biopsies were performed before (time = 0), during therapy (time = 3, 7, and 14 days), and after recurrence.

2024-05-31 | GSE240308 | GEO

A Novel Molecular Target in Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer treated with a Combination of Osimertinib and Pemetrexed

Project description:In this study, we evaluate the therapeutic potential of combining osimertinib with pemetrexed and clarify the underlying molecular mechanisms in order to establish novel therapeutic strategies for EGFR-mutant NSCLC. We found that the combination of osimertinib and pemetrexed could induce strong apoptotic activity and enhance anti-tumor effects compared to monotherapy in two NSCLC cell lines harboring an EGFR mutation. In addition, we have identified PLK1 as a therapeutic target for combination therapy and as a promising treatment target for overcoming resistance to osimertinib in EGFR-mutated NSCLC patients.

2021-10-14 | GSE165029 | GEO

Randomized Phase II Study of Pemetrexed Versus Gefitinib in Previously Treated Patients with Advanced Non-small Cell Lung Cancer.

Project description: Not available

| S-EPMC4720098 | biostudies-literature